<DOC>
	<DOCNO>NCT00069316</DOCNO>
	<brief_summary>Investigators assess whether Omr-IgG-am ( Trademark ) , intravenous immunoglobulin ( IVIg ) contain antibody specific West Nile virus ( WNV ) , safe well-tolerated patient suspect laboratory diagnose WNV disease . An initial estimation efficacy also make . This Phase I/II study enroll hospitalize adult presumptive diagnosis West Nile encephalitis and/or myelitis positive laboratory test diagnosis WNV infection high risk progress severe neurologic disease base age immunosuppression . Patients randomize block five receive either Omr-IgG-am ( Trademark ) , Polygam ( Registered Trademark ) S/D ( IVIG contain minimal anti-WNV antibody ) normal saline ratio 3:1:1 . Patients investigator blind treatment assignment . Patients receive single intravenous dose study medication one two placebo . The study participant receive 0.5 grams/kg Omr-IgG-am ( Trademark ) Polygam ( Registered Trademark ) S/D comparable volume normal saline . All patient follow safety , natural history endpoint , efficacy . A subset patient pharmacokinetic measurement specific anti- WNV antibody assess follow treatment . The primary endpoint safety tolerability follow Omr-IgG-am ( Trademark ) administration . Secondary endpoint include pharmacokinetics specific anti-WNV antibody , mortality confirm WNV positive patient , combination mortality functional status three month confirm WNV-infected patient patient intention treat . This combined endpoint measure use four standardized measure cognitive functional status : Barthel Index ; Modified Rankin Scale ; Glasgow Outcome Score ; Modified Mini-Mental Status Examination . A comparison outcomes make group receive Omr-IgG-am ( Trademark ) versus receive either placebo , two placebo group . Other secondary endpoint include proportion patient group return pre-morbid baseline subject 's improvement 3 month compare subject 's bad ( previous ) evaluation . Natural history endpoint also assess . They include duration intensive care unit ( ICU ) hospital stay , development persistence WNV-specific IgG IgM antibody , combine functional score mortality 3 month group encephalitis and/or myelitis baseline versus group positive WNV test , outcomes patient treat late coma correlation outcome time-to-treatment follow symptom onset .</brief_summary>
	<brief_title>Omr-IgG-am ( Trademark ) Treating Patients With High Risk West Nile Virus Disease</brief_title>
	<detailed_description>Investigators assess whether Omr-IgG-am ( Trademark ) , intravenous immunoglobulin ( IVIg ) contain antibody specific West Nile virus ( WNV ) , safe well-tolerated patient suspect laboratory diagnose WNV disease . An initial estimation efficacy also make . This Phase I/II study enroll hospitalize adult presumptive diagnosis West Nile encephalitis and/or myelitis positive laboratory test diagnosis WNV infection high risk progress severe neurologic disease base age immunosuppression . Patients randomize block five receive either Omr-IgG-am ( Trademark ) , Polygam ( Registered Trademark ) S/D ( IVIG contain minimal anti-WNV antibody ) normal saline ratio 3:1:1 . Patients investigator blind treatment assignment . Patients receive single intravenous dose study medication one two placebo . The study participant receive 0.5 grams/kg Omr-IgG-am ( Trademark ) Polygam ( Registered Trademark ) S/D comparable volume normal saline . All patient follow safety , natural history endpoint , efficacy . A subset patient pharmacokinetic measurement specific anti- WNV antibody assess follow treatment . The primary endpoint safety tolerability follow Omr-IgG-am ( Trademark ) administration . Secondary endpoint include pharmacokinetics specific anti-WNV antibody , mortality confirm WNV positive patient , combination mortality functional status three month confirm WNV-infected patient patient intention treat . This combined endpoint measure use four standardized measure cognitive functional status : Barthel Index ; Modified Rankin Scale ; Glasgow Outcome Score ; Modified Mini-Mental Status Examination . A comparison outcomes make group receive Omr-IgG-am ( Trademark ) versus receive either placebo , two placebo group . Other secondary endpoint include proportion patient group return pre-morbid baseline subject 's improvement 3 month compare subject 's bad ( previous ) evaluation . Natural history endpoint also assess . They include duration intensive care unit ( ICU ) hospital stay , development persistence WNV-specific IgG IgM antibody , combine functional score mortality 3 month group encephalitis and/or myelitis baseline versus group positive WNV test , outcomes patient treat late coma correlation outcome time-to-treatment follow symptom onset .</detailed_description>
	<criteria>INCLUSION CRITERIA : In order participate clinical trial , subject ( legal representative ) must provide write informed consent . Only patient meet entry criterion enrol . Eligible subject must fall one two category : A. Hospitalized patient great equal 18 year age encephalitis and/or myelitis define : New neurologic abnormality : Asymmetric extremity weakness without sensory abnormality ; Other neurologic abnormality ( include alter level consciousness , dysarthria dysphagia ) plus fever ( subjective objective ) within previous 4 day AND CSF examination within previous 96 hour show : Absence organism gram fungal stain White blood cell count great equal 4 per mm ( 3 ) correct significant red blood cell contamination . Ratio CSF : plasma glucose great equal 40 % ( CSF glucose/plasma glucose great equal 0.4 ) OR B. Hospitalized patient without encephalitis and/or myelitis define meet follow criterion : A positive IgM serology PCR test WNV blood cerebrospinal fluid , AND Clinical illness compatible WNV infection describe occurrence great equal 3 follow finding precede less equal 10 day : Diarrhea , headache , fever great 38 degree Celsius , nausea and/or vomiting , myalgia and/or arthralgia , nuchal rigidity , macular papular rash , new neurological abnormality AND A risk factor development WNV neurologic disease define : Age great equal 40 year , Age great equal 18 year , plus immunosuppression , define follow : Hematologic malignancy , previous diagnosis diabetes mellitus , chemotherapy within previous 4 week , stem cell transplant recipient solid organ transplant recipient , take immunosuppressive medication , include prednisone great equal 7.5 mg/day within previous 4 week , history human immunodeficiency virus ( HIV ) infection , congenital immunodeficiency syndrome ( include common variable immunodeficiency ) EXCLUSION CRITERIA : Unable obtain valid informed consent History intolerance ( include anaphylaxis ) IVIg related compound Known history IgA deficiency Known history hypersensitivity maltose . History ( time study entry ) hyperviscosity syndrome include limit : Waldenstrom 's macroglobulinemia Multiple myeloma Total white blood cell count great 80,000/mm ( 3 ) Hematocrit great 55 % Platelet count great 700,000/mm ( 3 ) Meets criteria Class III IV New York Heart Association Classification congestive heart failure patient Serum creatinine great 2.5 mg/dL require dialysis Alternate explanation ( determined investigator ) clinical finding ( structural brain lesion , cerebrovascular accident , infectious disease , include confirm infection flavivirus ) Pregnant breastfeed ( negative serum urine pregnancy test within previous 72 hour woman postmenopausal surgically sterilize ) Investigator 's opinion patient would unable adhere protocol requirement Receipt ribavirin , interferon alpha , intravenous immunoglobulin investigational drug treatment WNV hepatitis within 15 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 18, 2011</verification_date>
	<keyword>West Nile Virus</keyword>
	<keyword>Encephalitis</keyword>
	<keyword>Virus</keyword>
	<keyword>Mosquito</keyword>
	<keyword>Fever</keyword>
	<keyword>WNV</keyword>
	<keyword>Myelitis</keyword>
</DOC>